Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)

Area of Science:

• Oncology
• Molecular Biology
• Developmental Biology

Background:

• Vascular Endothelial Growth Factor (VEGF) signaling via VEGFR2 is crucial for tumor angiogenesis.
• VEGF signaling plays a role in embryonic development, vessel homeostasis, and tumor growth.
• FGFR signaling inhibition is also explored as an anti-angiogenic strategy.

Purpose of the Study:

• To investigate the gene dosage effects of VEGFR2, FGFR1, and FGFR2 in mouse models of tumorigenesis.
• To determine the role of endothelial versus hematopoietic VEGFR2 in tumor growth.
• To explore potential synergy between VEGFR2 and FGFR signaling in tumor angiogenesis.

Main Methods:

• Three independent mouse models of tumorigenesis were used: skin chemical carcinogenesis, B16F0 melanoma, and Lewis Lung Carcinoma (LLC) transplantation.
• Gene dosage effects were studied by creating mice with varying alleles of Vegfr2, Fgfr1, and Fgfr2.
• Tumor growth and angiogenesis were assessed in genetically modified mice.

Main Results:

• Mice heterozygous for Vegfr2 showed significant defects in tumor growth and angiogenesis.
• Deletion of endothelial Fgfr1 and Fgfr2 in Vegfr2 heterozygous mice did not alter tumor growth or angiogenesis compared to Vegfr2 heterozygotes.
• Hematopoietic deletion of Vegfr2 had minimal impact on tumor growth and angiogenesis, highlighting the importance of endothelial VEGFR2.

Conclusions:

• VEGFR2 exhibits critical gene dosage effects in regulating tumor angiogenesis.
• Endothelial FGFR1 and FGFR2 signaling do not appear to synergize with VEGFR2 in promoting tumor growth.
• Targeting VEGFR2 dosage is a key consideration for anti-angiogenic cancer therapies.